RxDoctor Payments DataLook up a doctor →

Isam Diab, MD

Rheumatology · Middleburg Hts, OHNPI 1063488765

Payments from drug & device makers

$15,289,806in general payments, 2019–2025

Across 2,390 payments — averaging $6397.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$8M
  • Novartis$2.2M
  • AbbVie$1.8M
  • Sun Pharmaceutical Industries Inc.$854K
  • Amgen$585K
  • E.r. Squibb & Sons, L.L.C.$426K
  • plus $1.3M from 54 others
$37,303in research payments, 2019–2025

Across 18 payments — averaging $2072.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$36K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$75

What the payments were for

  • Consulting fees$6,08817%
  • Speaking & faculty fees$3,48010%
  • Travel & lodging$1,8615%
  • Food & beverage$23,57366%
  • Education$5902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly106$8,025,102
Novartis127$2,239,852
AbbVie(2 entities)382$1,839,219
Sun Pharmaceutical Industries Inc.372$854,098
Amgen(2 entities)326$584,957
E.r. Squibb & Sons, L.L.C.72$425,929
Gilead55$306,710
Janssen Research & Development, LLC23$235,663
Genentech, Inc.10$199,550
Astrazeneca UK Limited7$139,686
Takeda Pharmaceuticals U.S.A., Inc.13$128,753
Mallinckrodt Enterprises LLC16$52,142
Aurinia Pharma U.S., Inc.24$48,890
Pfizer118$39,112
Roche Products Limited4$32,928
CSL Behring27$31,381
Bristol Myers Squibb3$24,000
AstraZeneca(2 entities)56$22,081
Biogen1$18,358
Kiniksa Pharmaceuticals International, PLC15$17,051
Mallinckrodt Hospital Products Inc.52$10,389
Lilly USA, LLC51$4,266
Johnson & Johnson(3 entities)127$2,293
UCB, Inc.131$2,150
Kiniksa Pharmaceuticals, Ltd.24$949
Genentech USA, Inc.61$897
GSK37$554
Radius Health, Inc.20$379
Organon11$241
Boehringer Ingelheim10$201
United Therapeutics Corporation5$149
Sobi, Inc8$145
Actelion Pharmaceuticals US, Inc.8$128
Fresenius Kabi USA, LLC7$128
Sanofi6$120
ANI Pharmaceuticals, Inc.6$116
Inspire Medical Systems, Inc.1$97
Biohaven Pharmaceuticals, Inc.5$94
Regeneron Healthcare Solutions, Inc.4$91
Merck7$90
Antares Pharma, Inc.4$75
Painteq LLC1$56
Supernus Pharmaceuticals, Inc.3$54
Jazz Pharmaceuticals Inc.4$54
Hikma Pharmaceuticals USA4$53
Sanofi-aventis U.S. LLC3$51
Arbor Pharmaceuticals, Inc.4$51
Biohaven Pharmaceutical Holding Company Ltd.3$47
Medexus Pharma, Inc.3$40
Eisai Inc.2$36
Azurity Pharmaceuticals, Inc.2$33
Sebela Pharmaceuticals Inc.2$29
Almatica Pharma LLC1$28
Ultragenyx Pharmaceutical Inc.2$26
Incyte Corporation1$24
Biocon Biologics Inc1$24
Xeris Pharmaceuticals, Inc.1$23
Assertio Therapeutics, Inc.1$20
Kyowa Kirin, Inc.1$19
Pacira Therapeutics, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,289,806 in reported general payments places this provider in the 95th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,055,380
Medicare patients
801
Services billed
114,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin12$530,456
Humira(Cf) PenAdalimumab35$300,092
Enbrel SureclickEtanercept19$193,838
Orencia ClickjectAbatacept18$103,844
Humira(Cf)Adalimumab14$92,551
Xeljanz XrTofacitinib Citrate12$67,672
OtezlaApremilast13$64,195
Hydroxychloroquine Sulfate1,171$47,022
Leflunomide517$31,327
MethotrexateMethotrexate Sodium938$30,388
Celecoxib462$23,966
SavellaMilnacipran Hcl26$19,118
Pregabalin318$11,496
Pilocarpine Hcl114$10,934
Prednisone1,119$10,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$10,389$530,45612 claims
AbbVieHumira(Cf), Savella$1,839,219$111,66940 claims
AmgenOtezla$584,957$64,19513 claims
Hikma Pharmaceuticals USAMitigare$53$4,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Middleburg Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →